Table 2.
Main decision-tree inputs
| Input | Reference | |
|---|---|---|
| Invalid results and positivity rate of selected biomarkers | ||
| EGFR (% positive / % invalid) | 13.6% / 1.70% | [15] |
| ALK (% positive / % invalid) | 3.4% / 2.60% | [15] |
| ROS1 (% positive / % invalid) | 1.0% / 3.30% | [15] |
| PD-L1 (TPS ≥ 50%) (% positive / % invalid) | 32.5% / 1.00% | Expert panel / [15] |
| Probability of re-biopsy | ||
| Percentage of invalid results re-biopsied | 33.3% | Expert panel |
| ROS1 determination strategies | ||
| IHC | 10.0% | Expert panel |
| FISH | 30.0% | Expert panel |
| REFLEX to FISH | 55.0% | Expert panel |
| NGS | 5.0% | Expert panel |
EGFR Epidermal growth factor receptor, ALK Anaplastic lymphoma kinase, ROS1 C-ros oncogene 1, PD-L1 Programmed death-ligand 1, IHC Immunohistochemistry, FISH Fluorescent in situ hybridization, NGS Next-generation sequencing